Table 4.
Multivariate analysis of factors associated with the risk of death among patients with NEC.
| HR (95%CI) | p Value | |
|---|---|---|
| Model 1: Rbinap | ||
| Lung primary (vs. other locations) | 1.61 (0.87–2.99) | 0.131 |
| SCNEC (vs. LCNEC) | 0.69 (0.37–1.27) | 0.230 |
| Ki-67 (each additional 1%) | 1 (1.00–1.02) | 0.166 |
| Extra-hepatic metastases | 1.95 (1.12–3.25) | 0.010 |
| Rbinap (vs. Rbapp) | 0.54 (0.31–0.95) | 0.033 |
| Model 2: Rb < 150 | ||
| Lung primary (vs. other locations) | 1.56 (0.84–2.91) | 0.157 |
| SCNEC (vs. LCNEC) | 0.74 (0.40–1.39) | 0.350 |
| Ki-67 (each additional 1%) | 1.01 (1–1.02) | 0.151 |
| Extra-hepatic metastases | 2.03 (1.21–3.41) | 0.007 |
| Rb < 150 (vs. Rb score ≥ 150) | 0.50 (0.25–1.01) | 0.053 |
| Model 3: p16high | ||
| Lung primary (vs. other locations) | 1.55 (0.82–2.95) | 0.179 |
| SCNEC (vs. LCNEC) | 0.79 (0.39–1.59) | 0.507 |
| Ki-67 (each additional 1%) | 1.01 (1–1.02) | 0.172 |
| Extra-hepatic metastases | 2.08 (1.24–3.49) | 0.005 |
| p16high (vs. p16low) | 0.52 (0.26–1.05) | 0.067 |
HR, Hazard ratio; 95%CI, 95% confidence interval; SCNEC, small-cell neuroendocrine carcinoma; LCNEC, large-cell neuroendocrine carcinoma; NEN, neuroendocrine neoplasm.